17 – 20 September 2023 Atriva Therapeutics to present at 9th European Scientific Working Group on Influenza (ESWI) Conference in Valencia

Our non-clinical activities yielded promising results in influenza and SARS-CoV-2 cell line studies and animal studies. We’re now planning the Phase 2 “SURVIVE” trial to explore zapnometinib’s efficacy as the first treatment for patients hospitalized with severe influenza. Visit our poster presentation at ESWI and learn more about Atriva and zapnometinib. For further information, you can also contact us at info@atriva-therapeutics.com